AlzFormer:使用MRI和图形嵌入的人口统计指导的适应性注意力门的阿尔茨海默氏症分类多模式框架
Sayyed Shahid Hussain1, Xu Degang1, Pir Masoom Shah2
1School of Automation, Central South University, Changsha, 410083, China.
概括
这项研究介绍了AlzFormer,这是一种用于阿尔茨海默病 (AD) 分类的新型深度学习模型. AlzFormer有效地整合了3DMRI和人口数据, 以提高这种具有挑战性的神经退行性疾病的诊断准确性.
科学领域:
- 神经科学
- 医学成像
- 人工智能
背景情况:
- 阿尔茨海默病 (AD) 是主要的死亡原因,由于微妙的脑部变化和人口统计数据的有限整合,这给诊断带来了重大挑战.
- 目前的机器学习模型与扩散病理,非统一的MRI变化和人口背景作斗争,阻碍了AD的准确分类.
- 及早及准确地发现AD对于有效的患者管理和治疗至关重要.
研究的目的:
- 开发一个新的多模式深度学习框架,AlzFormer,用于增强阿尔茨海默病的分类.
- 解决捕获全球病理,处理多层MRI数据和在AD检测中整合人口信息的局限性.
- 通过结合3DMRI和人口特征来提高自动化AD诊断的准确性和稳定性.
主要方法:
- 提出了一个多式深度学习框架,AlzFormer,集成3D卷积神经网络 (CNN) 进行体积特征和并行2DCNN与三平面MRI分析的转换器编码器.
- 纳入人口特征作为知识图嵌入使用新的自适应注意力门机制以动态平衡MRI和人口数据贡献.
- 在两个真实数据集上进行了全面的实验,包括概括,消去和强度测试.
主要成果:
- 在多个数据集中,AlzFormer模型在阿尔茨海默病分类中表现出强大而有效的性能.
- 废弃研究和稳定性评估证实了该模型在噪音条件下的有效性及其概括能力.
- 拟议的框架成功地整合了3DMRI和人口数据,通过解决关键的局限性,超越了现有的方法.
结论:
- AlzFormer为阿尔茨海默病诊断提供了一种强大且可解释的解决方案, 显著提高了诊断准确度.
- 该模型能够整合多模式数据,这表明该模型有可能融入临床决策支持系统 (CDSS).
- 这种方法为更个性化,更准确的阿尔茨海默病早期检测铺平了道路.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.0K
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
